Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs

References

• Hochberg M, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin. 2008;24:3029–3035. doi:10.1185/03007990802434932
   PubMed Web of Science ®Google Scholar
• Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010;30:357–363. doi:10.1007/s00296-009-0969-5
   PubMed Web of Science ®Google Scholar
• Zeng C, Wei J, Li H, et al. Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep. 2015;5:16827. doi:10.1038/srep16827
   Web of Science ®Google Scholar
• Hochberg MC, Martel-Pelletier J, Monfort J, et al.; MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75:37–44. doi:10.1136/annrheumdis-2014-206792
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Raynauld JP, Beaulieu AD, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016;18:256. doi:10.1186/s13075-016-1149-0
   PubMed Web of Science ®Google Scholar
• Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76:1537–1543. doi:10.1136/annrheumdis-2016-210860
   PubMed Web of Science ®Google Scholar
• Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, Acosta-Olivo CA, Peña-Martínez VM, Simental-Mendía LE. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018;38:1413–1428. doi:10.1007/s00296-018-4077-2
   Web of Science ®Google Scholar
• Zhu X, Sang L, Wu D, Rong J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018;13:170. doi:10.1186/s13018-018-0871-5
   PubMed Web of Science ®Google Scholar
• Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. doi:10.1136/bmj.c4675
   PubMed Web of Science ®Google Scholar
• Giacovelli G, Rovati LC. Glucosamine and osteoarthritis. Conclusions not supported by methods and results. BMJ. 2010;341:c6338.
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Hochberg MC, Du Souich P, Kahan A, Michel BA. Glucosamine and osteoarthritis. Effect size is encouraging. BMJ. 2010;341:c6328. doi:10.1136/bmj.c6328
   PubMed Web of Science ®Google Scholar
• Reginster JY, Altman RD, Hochberg MC. Glucosamine and osteoarthritis. Prescribed regimen is effective. BMJ. 2010;341:c6335. doi:10.1136/bmj.c6335
   PubMed Web of Science ®Google Scholar
• Panel of Experts of the Spanish Society of Rheumatology (SER). First consensus document of the Spanish Society of Rheumatology on the pharmacological treatment of knee osteoarthritis. Reumatol Clin. 2005;1:38–48. doi:10.1016/S1699-258X(05)72711-X
   Google Scholar
• Benito-Ruiz P. Guías y recomendaciones para el diagnóstico y tratamiento de la artrosis: en busca del consenso. [Guidelines and recommendations for the diagnosis and treatment of osteoarthritis: in search of consensus]. Sem Fund Esp Reumatol. 2012;13(Suppl 1):1–32.
   Google Scholar
• Jordan KM, Arden, NK, Doherty M, et al. EULAR recommendations 2003: an evidenced based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155. doi:10.1136/ard.2003.011742
   PubMed Web of Science ®Google Scholar
• Bruyere O, Reginster J-Y. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging. 2007;24(7):573–580. doi:10.2165/00002512-200724070-00005
   PubMed Web of Science ®Google Scholar
• Honvo G, Reginster JY, Rabenda V, et al. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):65–99. doi:10.1007/s40266-019-00662-z
   PubMed Web of Science ®Google Scholar
• Bernad M. Situación actual de los SYSADOA en España. [Current situation of the SYSADOA in Spain]. (Editorial). Reumatol Clin. 2016;12:181–183. doi:10.1016/j.reuma.2016.03.012
   Google Scholar
• Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013;108:392–400. doi:10.1038/ajg.2012.467
   PubMed Web of Science ®Google Scholar
• Instituto de Investigación en Atención Primaria Jordi Gol. Riesgo cardiovascular en pacientes con osteoartritis: estudio de casos y controles. [Cardiovascular risk in patients with osteoarthritis: case-control study]. Code: IJG-M01-2012-01. November 18, 2014.
   Google Scholar
• Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of nonsteroidal anti-inflammatory drug prescriptions with kidney disease among active young and middle-aged adults. JAMA Netw Open. 2019;2:e187896. doi:10.1001/jamanetworkopen.2018.7896
   Web of Science ®Google Scholar
• Rubio-Terrés C; Grupo del estudio VECTRA. Evaluación económica del uso de CS y antiinflamatorios no esteroideos en el tratamiento de la artrosis. Datos del estudio VECTRA. [Economic evaluation of the use of CS and non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis. Data from the VECTRA study]. Reumatol Clin. 2010;6:187–195. doi:10.1016/j.reuma.2009.12.009
   Google Scholar
• Rubio-Terrés C, Rubio-Rodríguez D, Möller I. Aproximación al impacto presupuestario y sanitario de la prescripción de CS en el tratamiento de la artrosis de rodilla y manos en comparación con los antiinflamatorios no esteroideos en Cataluña. [Approach to the budgetary and health impact of the prescription of SC in the treatment of osteoarthritis of the knee and hands in comparison with non-steroidal anti-inflammatory drugs in Catalonia]. Pharmacoecon Span Res Artic. 2017;14(1):19–25. doi:10.1007/s40277-016-0066-6
   Google Scholar
• Anguita P, González C, Cañete M, Rubio-Rodríguez D, Rubio-Terrés C. Coste de los efectos adversos asociados a enzalutamida o apalutamida en el tratamiento del cáncer de próstata resistente a la castración no metastásico en España. [Cost of adverse effects associated with enzalutamide or apalutamide in the treatment of non-metastatic castration-resistant prostate cancer in Spain]. Rev Esp Econ Salud. 2019;14:794–805.
   Google Scholar
• Manito N, Rubio-Rodríguez D, González J, et al. Análisis económico del tratamiento ambulatorio intermitente con levosimendán de la insuficiencia cardiaca en España. [Economic analysis of intermittent outpatient treatment with levosimendan for heart failure in Spain]. Rev Esp Cardiol. 2019. doi:10.1016/j.recesp.2019.06.019
   Web of Science ®Google Scholar
• Rubio-Terrés C, Rubio-Rodríguez D. Probabilistic analysis: sensitivity analysis or main result? (Editorial). Pharmacoeconomics. 2016;1:2. doi:10.4172/pe.1000e102
   Google Scholar
• Rubio-Terrés C, Rubio-Rodríguez D. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res. 2017;9:31–38.
   Web of Science ®Google Scholar
• Turnes J, García F, Diago M, et al. Impacto económico de la optimización de los recursos asistenciales en el abordaje del paciente con hepatitis C. Gastroenterol Hepatol. 2019;42(Suppl 1):26–33. doi:10.1016/S0210-5705(20)30185-0
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford, UK: Oxford University Press; 2006.
   Google Scholar
• Seoane-Mato D, Sánchez-Piedra C, Díaz-González F, Bustabad S; EPISER 2016 working group. Prevalence of rheumatic disease in adult population in Spain. EPISER 2016 study. Ann Rheum Dis. 2018;77.
   Google Scholar
• INE [Spanish National Statistics Institute]. Población y fenómenos demográficos nacionales. Población residente en España a 1 de enero, por sexo, edad y año. [Population and national demographic phenomena. Population resident in Spain by sex, age and year]. Available from: http://www.ine.es/. Accessed October 14, 2019.
   Google Scholar
• Wilson N, Sanchez-Riera L, Morros R, et al. Drug utilization in patients with OA: a population-based study. Rheumatol (Oxf). 2015;54:860–867. doi:10.1093/rheumatology/keu403
   PubMed Web of Science ®Google Scholar
• CONDROSAN 400 mg hard capsules. CONDROSAN 400 mg granulate for oral solution. Summary of product characteristics. Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/64549/FT_64549.pdf. Accessed September 17, 2019.
   Google Scholar
• DROGLICAN 200 mg/250 mg hard capsules. Summary of product characteristics. Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/71394/FT_71394.pdf. Accessed September 17, 2019.
   Google Scholar
• A trial of GI safety of celecoxib compared with non-selective nonsteroidal antiinflammatory drugs (NSAIDS) (GI-REASONS). Available from: https://clinicaltrials.gov/ct2/show/results/NCT00373685?term=GI-REASONS&draw=2&rank=1. Accessed November 21, 2019.
   Google Scholar
• AEMPS [Spanish Agency of Medcines and Medical Devices]. Utilización de medicamentos antiinflamatorios no esteroideos en España durante el periodo 2013–2016. Informe de utilización de medicamentos U/AIN/V1/11/09/2017. [Use of non-steroidal anti-inflammatory drugs in Spain during the 2013-2016 period. Drug use report U / AIN / V1 / 11/09/2017]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/antiinflamatorios-AINEs-periodo-2013-2016.pdf. Accessed September 17, 2019.
   Google Scholar
• Catalan Institute of Health. Resolution SLT/353/2013 dated 13 February on the revision of public prices corresponding to the health services provided by the Catalan Institute of Health. Official Gazette of the Government of Catalonia; March 1, 2013: 6326.
   Google Scholar
• De Abajo FJ, Gil MJ, García Poza P, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23:1128–1138. doi:10.1002/pds.3617
   PubMed Web of Science ®Google Scholar
• García-Poza P, de Abajo FJ, Gil MJ, Chacón A, Bryant V, García-Rodríguez LA. Risk of ischemic stroke associated with nonsteroidal anti-inflammatory drugs and paracetamol: a population-based case-control study. J Thromb Haemost. 2015;13:708–718. doi:10.1111/jth.12855
   PubMed Web of Science ®Google Scholar
• ORDER 727/2017, dated 7 August, of the Regional Minister of Health, setting the public prices for the provision of health services and activities of the network of centres in the Community of Madrid. Official Gazette of the Community of Madrid No. 198;August 21, 2017.
   Google Scholar
• BotPlus. Available from: https://botplusweb.portalfarma.com/. Accessed November 21, 2019.
   Google Scholar
• Agrupación homogénea de las presentaciones de los medicamentos para pacientes no hospitalizados que requieren para su dispensación receta médica oficial u orden de dispensación, junto con el precio vigente [Homogeneous grouping of the presentations of outpatient medicines that require an official prescription or dispensing order for their dispensing, together with the current price]. Available from: https://www.mscbs.gob.es/profesionales/farmacia/pdf/AGRUPACIONES_HOMOGENEAS_MEDICAMENTOS.pdf. Accessed September 17, 2019.
   Google Scholar